Seattle Genetics Inc (SGEN)

63.57
0.90 1.40
NASDAQ : Health Care
Prev Close 64.47
Open 64.43
Day Low/High 63.45 / 65.40
52 Wk Low/High 26.02 / 50.67
Volume 651.64K
Avg Volume 936.40K
Exchange NASDAQ
Shares Outstanding 142.49M
Market Cap 9.18B
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Immunomedics Soars on Injunction Against Seattle Genetics Deal

Immunomedics Soars on Injunction Against Seattle Genetics Deal

The biotech company embattled by activist investor VenBio may not be able to go through with its licensing deal.

FDA Lifts Clinical Hold On Seattle Genetics' Phase 1 Trials Of Vadastuximab Talirine

FDA Lifts Clinical Hold On Seattle Genetics' Phase 1 Trials Of Vadastuximab Talirine

Seattle Genetics, Inc. (Nasdaq:SGEN), a global biotechnology company, today announced that the U.

Activist Investor Wins Control of Immunomedics Board Following Shareholder Vote

Activist Investor Wins Control of Immunomedics Board Following Shareholder Vote

The newly reconstituted Immunomedics board is likely to start a search for a new CEO and could either renegotiate the IMMU-132 deal with Seattle Genetics or cancel it.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Seattle Genetics Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of March 13, 2017

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Seattle Genetics Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of March 13, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Seattle Genetics Inc.

Seattle Genetics To Present At Upcoming Investor Conferences

Seattle Genetics To Present At Upcoming Investor Conferences

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences.

SGEN SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Seattle Genetics Inc. And A Lead Plaintiff Deadline Of March 13, 2017

SGEN SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Seattle Genetics Inc. And A Lead Plaintiff Deadline Of March 13, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington on behalf of investors who purchased Seattle Genetics Inc.

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Seattle Genetics Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of March 13, 2017 - SGEN

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Seattle Genetics Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of March 13, 2017 - SGEN

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Seattle Genetics Inc.

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Seattle Genetics Inc. To Contact The Firm

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Seattle Genetics Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Western District of Washington on behalf...

Activist Investor to Block Partnership of Immunomedics and Seattle Genetics

Activist Investor to Block Partnership of Immunomedics and Seattle Genetics

The largest shareholder of Immunomedics, VenBio, asks for an injunction against its partnership with Seattle Genetics.

Activist Investor Seeks Legal Block of Immunomedics Cancer Drug Partnership With Seattle Genetics

Activist Investor Seeks Legal Block of Immunomedics Cancer Drug Partnership With Seattle Genetics

VenBio accuses Immunomedics management of undervaluing and essentially giving away the cancer drug IMMU-132 because they were afraid of losing their jobs in a proxy vote.

SGEN SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Seattle Genetics Inc. And A Lead Plaintiff Deadline Of March 13, 2017

SGEN SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Seattle Genetics Inc. And A Lead Plaintiff Deadline Of March 13, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington on behalf of investors who purchased Seattle Genetics Inc.

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Sage Therapeutics, Immunomedics and Myriad Genetics were among the premarket biotech stock movers on Monday.

Seattle Genetics To Present At Leerink Partners 6th Annual Global Healthcare Conference

Seattle Genetics To Present At Leerink Partners 6th Annual Global Healthcare Conference

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15 at 2:30pm Eastern Time.

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

The companies inked a $250 million deal on Friday that could be worth up to $2 billion, thanks to milestone payments.

Immunomedics Announces Postponement Of 2016 Annual Meeting

Immunomedics Announces Postponement Of 2016 Annual Meeting

New Meeting Date Provides Time for Modified "Go-Shop" Period Negotiated in Global Licensing Agreement of IMMU-132 with Seattle Genetics to Have Expired or Otherwise Been Completed and Allows Stockholders to Carefully Consider the Significant Value Created by the Licensing Transaction

Immunomedics Enters Into Exclusive Global Licensing Agreement With Seattle Genetics For Sacituzumab Govitecan (IMMU-132) With Potential Payments Of Up To Approximately $2 Billion, Plus Royalties

Immunomedics Enters Into Exclusive Global Licensing Agreement With Seattle Genetics For Sacituzumab Govitecan (IMMU-132) With Potential Payments Of Up To Approximately $2 Billion, Plus Royalties

Immunomedics to Receive $250 Million in Upfront Cash Payment; Plus Among Other Milestone Payments, an Additional $50 Million or Negotiated Economic Splits Relating to Rights Outside US, Canada and EU

Seattle Genetics Announces Global License Agreement With Immunomedics For Sacituzumab Govitecan (IMMU-132), A Promising Late-Stage ADC For Solid Tumors

Seattle Genetics Announces Global License Agreement With Immunomedics For Sacituzumab Govitecan (IMMU-132), A Promising Late-Stage ADC For Solid Tumors

Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced a development and license agreement with Immunomedics, Inc.

Seattle Genetics Reports Fourth Quarter And Year 2016 Financial Results

Seattle Genetics Reports Fourth Quarter And Year 2016 Financial Results

Seattle Genetics, Inc. (NASDAQ:SGEN), a global biotechnology company, today reported financial results for the fourth quarter and year ended December 31, 2016.

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Seattle Genetics, Inc.

INVESTOR ALERT: Law Offices Of Howard G. Smith Commences Investigation On Behalf Of Seattle Genetics, Inc. Investors

INVESTOR ALERT: Law Offices Of Howard G. Smith Commences Investigation On Behalf Of Seattle Genetics, Inc. Investors

Law Offices of Howard G. Smith announces an investigation on behalf of Seattle Genetics, Inc.

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Seattle Genetics Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Seattle Genetics Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Western District of Washington on behalf...